Traws Pharma Inc (TRAW)

$0.77 -0.04 (-5.34%)
Market Cap 7.80M
Revenue (ttm) 2.79M
Net Income (ttm) 9.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 328.67%
Debt to Equity Ratio 0.00
Volume 238,500
Avg Vol 2,861,576
Day's Range N/A - N/A
Shares Out 10.16M
Stochastic %K 6%
Beta 1.51
Analysts Hold
Price Target $2.00

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also deve...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
Boywithathorn
Boywithathorn Jul. 2 at 10:10 PM
$TRAW This pos management better get stock over $1. What are we gonna do a 10/1 rs and have a 1 million shares outstanding? Lmfao. These old men are scum.
0 · Reply
Jbjb90
Jbjb90 Jul. 2 at 6:58 PM
$TRAW doing a nice job of bouncing off low of day, just need some sustained buying momentum, positive news would certainly help
0 · Reply
kyly2
kyly2 Jul. 2 at 5:59 PM
$TRAW up up up
0 · Reply
Jbjb90
Jbjb90 Jul. 2 at 3:40 PM
$TRAW overdue for some good news and a spike back up towards 2 bucks
2 · Reply
AllmightyDollah
AllmightyDollah Jul. 2 at 3:07 PM
$TRAW 20 to 1 outflow to inflow today. 4 Old men employee scam fest. No website update in 1 year. No conferences. Only paychecks. FDA and European agency tells the ex CDC chief to kick rocks. Does a 140 million shelf with a 11 million dollar cap. Complete and utter shiteshow.
0 · Reply
Dwarn2021
Dwarn2021 Jul. 1 at 10:23 PM
$TRAW they are worth at least $8. It will look bad and scary like it couldn’t get any worse, and then either assets will get bought out or Ebola or bird flu news will bring them back to reality. Either way the market cap should 5-8x just on the IP. I continue to buy.
3 · Reply
AllmightyDollah
AllmightyDollah Jul. 1 at 8:15 PM
$TRAW scammy scam scam. Told investers just weeks ago cash runaway till 2027. Lying scammy facks.
0 · Reply
Jbjb90
Jbjb90 Jul. 1 at 8:04 PM
$TRAW 🤦‍♂️https://www.stocktitan.net/sec-filings/TRAW/s-3-traws-pharma-inc-shelf-registration-statement-38f450fefd8f.html
1 · Reply
AllmightyDollah
AllmightyDollah Jul. 1 at 8:01 PM
$TRAW lol. Shite scamfest closes low of day. The 4 employee old men pos humans are so terrible.
0 · Reply
AllmightyDollah
AllmightyDollah Jun. 30 at 7:20 PM
$TRAW Outflow 27. Inflow 1. Utter shitshow with inept scamfest management.
0 · Reply
Latest News on TRAW
Traws Pharma files $139.19M mixed securities shelf

2026-07-01T20:05:19.000Z - 3 days ago

Traws Pharma files $139.19M mixed securities shelf

Traws Pharma Registration statement: Registration filing

Jul 1, 2026, 8:00 AM EDT - 3 days ago

Traws Pharma Registration statement: Registration filing

Traws Pharma provides update on tivoxavir marboxil program

2026-06-22T11:30:46.000Z - 12 days ago

Traws Pharma provides update on tivoxavir marboxil program

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Jun 22, 2026, 7:00 AM EDT - 12 days ago

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright

2026-06-18T11:27:11.000Z - 16 days ago

Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright

Traws Pharma downgraded to Neutral from Buy at Ladenburg

2026-06-15T10:52:38.000Z - 19 days ago

Traws Pharma downgraded to Neutral from Buy at Ladenburg

Traws Pharma influenza challenge study deferred following MHRA review

2026-06-12T21:40:11.000Z - 22 days ago

Traws Pharma influenza challenge study deferred following MHRA review

Traws Pharma Provides Regulatory Update on Influenza Program

Jun 12, 2026, 5:30 PM EDT - 22 days ago

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Traws Pharma Proxy statement: Proxy filing

Traws Pharma Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Traws Pharma Proxy statement: Proxy filing

Traws Pharma announces antiviral program targeting Hantavirus, Ebola

2026-05-27T13:04:01.000Z - 5 weeks ago

Traws Pharma announces antiviral program targeting Hantavirus, Ebola

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026, 8:45 AM EDT - 5 weeks ago

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Traws Pharma Proxy statement: Proxy filing

May 19, 2026, 8:00 AM EDT - 6 weeks ago

Traws Pharma Proxy statement: Proxy filing

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

Traws Pharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Traws Pharma Quarterly report: Q1 2026

Traws Pharma Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Traws Pharma Earnings release: Q1 2026

Traws Pharma files to sell 35.9M shares of common stock for holders

2026-05-08T22:46:20.000Z - 2 months ago

Traws Pharma files to sell 35.9M shares of common stock for holders

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

May 8, 2026, 1:43 PM EDT - 2 months ago

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma Registration statement: Registration filing

May 8, 2026, 8:00 AM EDT - 2 months ago

Traws Pharma Registration statement: Registration filing

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

May 8, 2026, 7:30 AM EDT - 2 months ago

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Earnings Call Transcript: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Earnings Call Transcript: Q4 2025

Traws Pharma Earnings release: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Earnings release: Q4 2025

Traws Pharma Annual report: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Annual report: Q4 2025

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Apr 15, 2026, 4:01 PM EDT - 2 months ago

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir

2026-02-19T12:43:19.000Z - 4 months ago

Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Feb 19, 2026, 7:30 AM EST - 4 months ago

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma initiated with a Buy at Ladenburg

2026-01-30T12:20:23.000Z - 5 months ago

Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

2026-01-26T13:35:09.000Z - 5 months ago

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

2026-01-13T12:05:30.000Z - 6 months ago

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Jan 13, 2026, 7:00 AM EST - 6 months ago

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

2025-12-17T11:11:13.000Z - 7 months ago

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

Traws Pharma initiated with a Buy at H.C. Wainwright

2025-12-03T11:10:09.000Z - 7 months ago

Traws Pharma initiated with a Buy at H.C. Wainwright

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

2025-11-13T12:05:59.000Z - 8 months ago

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

Traws Pharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Traws Pharma Quarterly report: Q3 2025

Traws Pharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Traws Pharma Earnings release: Q3 2025

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 30, 2025, 12:00 PM EDT - 8 months ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 22, 2025, 6:40 PM EDT - 9 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

2025-10-14T11:10:48.000Z - 9 months ago

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 14, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma appoints John Leaman as independent director

2025-10-06T11:37:17.000Z - 9 months ago

Traws Pharma appoints John Leaman as independent director

Traws Pharma receives approval to proceed with Phase 2 COVID studies

2025-08-18T11:05:38.000Z - 11 months ago

Traws Pharma receives approval to proceed with Phase 2 COVID studies

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 11 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Earnings Call Transcript: Q2 2025

Traws Pharma Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Earnings release: Q2 2025

Traws Pharma Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Quarterly report: Q2 2025

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

2025-08-14T11:16:52.000Z - 11 months ago

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 1 year ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 1 year ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Quarterly report: Q1 2025

Traws Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q1 2025

Traws Pharma Earnings Call Transcript: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q4 2024

Traws Pharma Annual report: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Annual report: Q4 2024

Traws Pharma Earnings release: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q4 2024

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 1 year ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Proxy statement: Proxy Filing

Feb 6, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Traws Pharma Registration statement: Registration Filing

Jan 15, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Registration statement: Registration Filing

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Quarterly report: Q3 2024

Traws Pharma Earnings release: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Earnings release: Q3 2024

Traws Pharma Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings Call Transcript: Q2 2024

Traws Pharma Quarterly report: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q2 2024

Traws Pharma Earnings release: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q2 2024

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Proxy statement: Proxy Filing

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Proxy statement: Proxy Filing

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Registration statement: Registration Filing

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Registration statement: Registration Filing

Traws Pharma Proxy statement: Proxy Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Quarterly report: Q1 2024

May 16, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q1 2024

Traws Pharma Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Transcript: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Transcript: M&A Announcement

Traws Pharma Press release: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Press release: M&A Announcement

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants

ONTX

Traws Pharma Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q4 2023

Traws Pharma Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Annual report: Q4 2023

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 2 years ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

ONTX

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

ONTX

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

ONTX

Traws Pharma Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Earnings Call Transcript: Q3 2023

Traws Pharma Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Quarterly report: Q3 2023

Traws Pharma Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Earnings release: Q3 2023

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

ONTX

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

ONTX

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

ONTX

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

ONTX

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

ONTX

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

ONTX

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

ONTX

Traws Pharma Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings Call Transcript: Q2 2023

Traws Pharma Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Quarterly report: Q2 2023

Traws Pharma Earnings release: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings release: Q2 2023

Traws Pharma Proxy statement: Proxy Filing

Jul 21, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Proxy statement: Proxy Filing

Traws Pharma Registration statement: Registration Filing

Jun 30, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Registration statement: Registration Filing

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

ONTX

Traws Pharma Proxy statement: Proxy Filing

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Proxy statement: Proxy Filing

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

ONTX

Boywithathorn
Boywithathorn Jul. 2 at 10:10 PM
$TRAW This pos management better get stock over $1. What are we gonna do a 10/1 rs and have a 1 million shares outstanding? Lmfao. These old men are scum.
0 · Reply
Jbjb90
Jbjb90 Jul. 2 at 6:58 PM
$TRAW doing a nice job of bouncing off low of day, just need some sustained buying momentum, positive news would certainly help
0 · Reply
kyly2
kyly2 Jul. 2 at 5:59 PM
$TRAW up up up
0 · Reply
Jbjb90
Jbjb90 Jul. 2 at 3:40 PM
$TRAW overdue for some good news and a spike back up towards 2 bucks
2 · Reply
AllmightyDollah
AllmightyDollah Jul. 2 at 3:07 PM
$TRAW 20 to 1 outflow to inflow today. 4 Old men employee scam fest. No website update in 1 year. No conferences. Only paychecks. FDA and European agency tells the ex CDC chief to kick rocks. Does a 140 million shelf with a 11 million dollar cap. Complete and utter shiteshow.
0 · Reply
Dwarn2021
Dwarn2021 Jul. 1 at 10:23 PM
$TRAW they are worth at least $8. It will look bad and scary like it couldn’t get any worse, and then either assets will get bought out or Ebola or bird flu news will bring them back to reality. Either way the market cap should 5-8x just on the IP. I continue to buy.
3 · Reply
AllmightyDollah
AllmightyDollah Jul. 1 at 8:15 PM
$TRAW scammy scam scam. Told investers just weeks ago cash runaway till 2027. Lying scammy facks.
0 · Reply
Jbjb90
Jbjb90 Jul. 1 at 8:04 PM
$TRAW 🤦‍♂️https://www.stocktitan.net/sec-filings/TRAW/s-3-traws-pharma-inc-shelf-registration-statement-38f450fefd8f.html
1 · Reply
AllmightyDollah
AllmightyDollah Jul. 1 at 8:01 PM
$TRAW lol. Shite scamfest closes low of day. The 4 employee old men pos humans are so terrible.
0 · Reply
AllmightyDollah
AllmightyDollah Jun. 30 at 7:20 PM
$TRAW Outflow 27. Inflow 1. Utter shitshow with inept scamfest management.
0 · Reply
AllmightyDollah
AllmightyDollah Jun. 29 at 10:07 PM
$TRAW Managements Coorporate Deck hasn’t been updated since early 2025. They go to no conferences. Last one on website was early 2025. Website hasn’t been updated since 2025. What an absolute joke of a pos scammy ass company.
0 · Reply
Boywithathorn
Boywithathorn Jun. 29 at 7:26 PM
$TRAW
0 · Reply
Boywithathorn
Boywithathorn Jun. 29 at 2:49 PM
$TRAW 48 outflow to 2 inflow. Embarrassing. Inept management.
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 29 at 1:44 PM
$TRAW can we get back to 1 dollar??!!! 🙏🐂
1 · Reply
Dwarn2021
Dwarn2021 Jun. 27 at 3:54 PM
$TRAW ebola response
0 · Reply
cjm_81
cjm_81 Jun. 27 at 2:26 AM
$TRAW https://www.reuters.com/business/healthcare-pharmaceuticals/cdc-raises-response-ebola-outbreak-highest-level-says-risk-spread-us-is-low-2026-06-26/
0 · Reply
kyly2
kyly2 Jun. 26 at 1:58 PM
$TRAW 🚀
0 · Reply
killer01
killer01 Jun. 25 at 9:51 PM
$TRAW just seems like right price to buy
0 · Reply
Dwarn2021
Dwarn2021 Jun. 25 at 4:12 PM
$TRAW Just picked up 7,500 more shares.
1 · Reply
Boywithathorn
Boywithathorn Jun. 25 at 2:57 PM
$TRAW XBI records high and this deep red of course.
0 · Reply
Jbjb90
Jbjb90 Jun. 25 at 1:50 PM
$TRAW slowly returning shares, if they have an update on the ebola program seems like a good week to release any preliminary positive findings
0 · Reply
Dwarn2021
Dwarn2021 Jun. 24 at 7:56 PM
$TRAW Interesting: https://srnnews.com/exclusive-trump-to-seek-more-than-1-4-billion-in-ebola-funding-from-congress/
2 · Reply